- Joined
- Dec 27, 2005
- Messages
- 89
- Reaction score
- 19
Need some confirmation or education on this. I think I know why but I have never read it or had it verbalized to me. When we have patients who are admitted to our hospital with CAP most patients are put on ceftriaxone/azithromycin. When there is a more severe pneumonia case or higher likelihood of MDR we will include cover pseudomonas and sometimes mrsa with cefepime/vanc or zosyn/vanc. So my question is when we “go broader” we lose the atypical coverage. I think this is because more severe cases are usually not attributed to atypical pathogens. Is my thinking correct?